Answers are grounded in this paper and cite their sources.
May support calcium channel blockade in calmodulinopathy; hypothesis-generating from hiPSC-CM models and requires clinical validation.
Calmodulinopathy is a life-threatening cardiac arrhythmia syndrome resulting from a heterozygous mutation in any of the three calmodulin (CaM) genes CALM1 , CALM2 , or CALM3 . Despite treatment with typical antiarrhythmic drug therapies, more than half of individuals with a pathogenic CALM variant experience major arrhythmic events such as aborted cardiac arrest or sudden cardiac death. Currently we have limited knowledge linking different CALM genetic variants to cellular phenotypes and the pharmacogenomic relationship between variant and potential drug therapy. To address this, we generated hiPSC-CMs from five CaM - LQTS patients harboring different heterozygous CALM variants and assessed in vitro function using a combination of assays for Ca 2+ dynamics, impedance, and extracellular and transmembrane voltage. We identified lower beat rate and prolonged Ca 2+ transients as common features of calmodulinopathic hiPSC-CMs. Microelectrode array and patch clamp recording of action potentials demonstrated that hiPSC-CMs with variants in EF-hand III have greater pulse width, longer action potential duration, and increased maximum upstroke velocity that were not observed in the EF-hand IV variant hiPSC-CMs. With an established in vitro phenotype detectable in multiparameter high-throughput assays, we tested a selection of four clinically relevant drugs for use as potential calmodulinopathy therapies. We observed that calcium channel blockers verapamil and diltiazem alleviated the CaM-LQTS phenotype in hiPSC-CMs with both the CALM2 D96G and D96V variants albeit at supratherapeutic doses. Our findings support clinical investigation of calcium channel blockade as a potential mechanistic target for calmodulinopathy and that hiPSC-CMs can facilitate the study calmodulinopathy therapies in a patient- and variant-specific manner.
No takes yet. Share an insight, caveat, or question.
Fetterman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: